Swedish firm Getinge to buy Paragonix Technologies for about $477 mln
Aug 22 (Reuters) -Swedish medical-equipment maker Getinge GETIb.ST said on Thursday it will acquire U.S.-based organ transport company Paragonix Technologies for about $477 million.
Getinge will acquire all the issued and outstanding shares of the privately-held Paragonix on a cash and debt-free basis, adding that the initial payout related to the acquisition will be financed through a bridge loan provided by Swedish bank SEB Group.
The acquisition is expected to have a slightly negative impact on Getinge's adjusted earnings per share in 2024, the Gothenburg-based company said in a press release.
Paragonix Technologies, headquartered in Waltham, Massachusetts, is a developer and manufacturer in the organ transplant industry, focused on improving patient outcomes through advanced organ preservation solutions, according to its website.
Getinge, in July, had beat second-quarter earnings forecasts, as its order intake rose despite some problems with its packaging and heart products.
Reporting by Rishabh Jaiswal in Bengaluru; Editing by Mohammed Safi Shamsi
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
